within Pharmacolibrary.Drugs.ATC.N;

model N05AL06
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 0.5,
    Cl             = 1.6666666666666667e-06,
    adminDuration  = 600,
    adminMass      = 100 / 1000000,
    adminCount     = 1,
    Vd             = 0.002,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.013333333333333334,
    Tlag           = 10.200000000000001
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>name:</td><td>Veralipride</td></tr><tr><td>ATC code:</td><td>N05AL06</td></tr><td>route:</td><td>oral</td></tr><tr><td>n-compartments</td><td>1</td></tr></table><p>Veralipride is a benzamide neuroleptic and dopamine D2 receptor antagonist that was used mainly for the treatment of vasomotor symptoms associated with menopause such as hot flashes. It is not approved or marketed in most countries today due to concerns over adverse effects and long-term safety.</p><h4>Pharmacokinetics</h4><p>Estimated typical pharmacokinetic parameters in healthy adult women, based on limited published data and general class properties (benzamide antipsychotics). No primary PK study with exact parameters available in PubMed or regulatory documentation.</p><h4>References</h4><ol><li><p>Csajka, C, et al., &amp; Verotta, D (2005). The use of a sum of inverse Gaussian functions to describe the absorption profile of drugs exhibiting complex absorption. <i>Pharmaceutical research</i> 22(8) 1227â€“1235. DOI:<a href=\"https://doi.org/10.1007/s11095-005-5266-8\">10.1007/s11095-005-5266-8</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/16078132/\">https://pubmed.ncbi.nlm.nih.gov/16078132</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial generated model</li></ul></body></html>"
  ));
end N05AL06;
